AT

Enjoying my sandwich

[AT @BioSyncopation]

@BernieSanders https://t.co/kHAtsI4YlB

[Stephen L. Miller @redsteeze]

Pretty fun watch.

[AT @BioSyncopation]

@GadSaad @BernieSanders https://t.co/kHAtsI4YlB

[Stephen L. Miller @redsteeze]

Pretty fun watch.

[Bio Stocks™ @BioStocks]

$ARTV $300M offering priced at $11.52/share

[AT @BioSyncopation]

$ARTV what's not to like?

[BioValues @BioValues]

$ARTV just had a late-breaking presentation posted for EULAR. Title bodes very well for outcome here in RA, etc. Likely why stock is moving:

[BioValues @BioValues]

$ARTV just had a late-breaking presentation posted for EULAR. Title bodes very well for outcome here in RA, etc. Likely why stock is moving:

[Josh @_j0sh_a_]

“Show me a map of Israel before 1948” 🤔

[AT @BioSyncopation]

@TTRAmyloid @dedwng From big pharma. Not short sellers.

[AT @BioSyncopation]

@Biohazard3737 Surge in 10-year treasury yield $XBI

[AT @BioSyncopation]

@dedwng True, however all of this was well known when $ERAS was at $7B.

[AT @BioSyncopation]

@dedwng Maybe. In any case $RVMD escaped so now what? $ERAS doesn't come with a $30B price tag either

[FBCC @BiotechPort]

$ERAS $ANL

$ERAS were idiots how they played this game. Should not have been dragged into $RVMD scenario and be reactive. Should have waited and released mature data.

But to say that Big Pharma will just give up a $10-15B market and leave it all to $RVMD is ridicules.
Saying "RVMD will get approved first and take the whole market" is plain stupid. Never happened before.
There are many strategies Big Pharma can play with: first line, combinations.....
There is no way, because there is just no way. that this market will be left to $RVMD to play in alone.
And there are only two ways you can play this theme in public markets : $ANL or $ERAS.

All in all I think $ANL is the winner from the late $RVMD - $ERAS debacle.

[AT @BioSyncopation]

Also, patent disputes are typically settled in courts. Do you really think big-pharma well just sit on their hands while and let $RVMD have a $9B market (only in PDAC) just for themselves? $ERAS $ANL

[AT @BioSyncopation]

$ERAS if PRMT5i combo a hit, what prevents $ERAS from initiating a ph3 trial at the same time as $RVMD? What stops $BMS from picking up $ERAS and competing with $RVMD neck-to-neck? Scratching off all strategic value from $ERAS due to a 2yrs lag is ridiculous.

[AT @BioSyncopation]

100% agree. $ERAS got a beating that may have been well deserved given the the bloated valuation and hastened data report, but remains, along with $ANL, the only playable RAS names. $ANL much cheaper and with less of a patent overhang should pickup ahead of data.

[Ohad Hammer @ohadhammer]

Putting criticism about timing and data presentation aside, $ERAS' ERAS-0015 seems very similar to $RVMD's daraxonrasib imo.

ERAS-0015 is more potent which explains the lower exposure required for efficacy (and associated with on target toxicity of course). It might have a slight advantage on GI side effects (to be seen) but other than that it is likely to have a similar therapeutic index.

If we compare just the PDAC data sets, $ERAS reported 4 PRs in 21 patients (~19% ORR) in the US at relevant doses which is lower than dara's 35% ORR but that gap will likely close with more follow up as $ERAS has multiple near PRs at the first scan than can convert in the future (They need 3 such conversions to reach 33% ORR).

The limited follow up probably has a confounding effect on safety as well (longer treatment typically leads to more side effects) which should take $ERAS to a similar dose interruption/reduction rate in the future. Gr5 pneumonitis case requires attention but it could be an isolated case.

Is $ERAS cheap at $3B? Not sure but for pharmas who cannot afford or simply won't get $RVMD this is the closest fast follower program that could be P3 ready later this year.

*no position in stocks mentioned *

[Ohad Hammer @ohadhammer]

Putting criticism about timing and data presentation aside, $ERAS' ERAS-0015 seems very similar to $RVMD's daraxonrasib imo.

ERAS-0015 is more potent which explains the lower exposure required for efficacy (and associated with on target toxicity of course). It might have a slight advantage on GI side effects (to be seen) but other than that it is likely to have a similar therapeutic index.

If we compare just the PDAC data sets, $ERAS reported 4 PRs in 21 patients (~19% ORR) in the US at relevant doses which is lower than dara's 35% ORR but that gap will likely close with more follow up as $ERAS has multiple near PRs at the first scan than can convert in the future (They need 3 such conversions to reach 33% ORR).

The limited follow up probably has a confounding effect on safety as well (longer treatment typically leads to more side effects) which should take $ERAS to a similar dose interruption/reduction rate in the future. Gr5 pneumonitis case requires attention but it could be an isolated case.

Is $ERAS cheap at $3B? Not sure but for pharmas who cannot afford or simply won't get $RVMD this is the closest fast follower program that could be P3 ready later this year.

*no position in stocks mentioned *

[AT @BioSyncopation]

$ERAS re lawsuite, anyone who follows this space closely couldn't be surprised. I view it as an acknowledgement by $RVMD that ERAS is a threat, despite the lag. Re data, I think they have a good molecule on their hands. With RVMD @ $30B, what other way to play RAS? $ERAS $ANL

[AT @BioSyncopation]

True, but most likely not a real signal given the context of the disease and history of the patient. Not a big deal IMHO. Overall tolerability profile is actually encouraging $ERAS

[WC @Sanctuary_Bio]

have to say

really not a great look to not disclose a death in the PR and only mention it in slides. If there really is no correlation, what's the issue

[AT @BioSyncopation]

So $ERAS got the letter from $RVMD on Friday and decided during the weekend to give a data update on Monday?

[Adam Feuerstein ✡️ @adamfeuerstein]

$ERAS pan-Ras data update this afternoon after market close.

also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents.

https://t.co/QTmyUhT89n

[CM @clinmean]

$WHWK PTK7-ADC 👌
https://t.co/XutBy6LVjw

[AT @BioSyncopation]

$IDYA biggest takeaway from the call is mgmt noting early separation of OS curves with 10m of follow up

[Jacob Plieth @JacobPlieth]

$IDYA PFS curves from Optimum-02